Plazza raises $15M from Accel, Elevation, Nexus to expand rapid medicine delivery

Healthtech startup Plazza, which is building a technology-led pharmacy retail and rapid medicine delivery platform, has raised $15 million in a Series A funding round co-led by Accel, Elevation Capital, and Nexus Venture Partners, with participation from existing investors All In Capital and Better Capital.

The Bengaluru-based company said it will use the fresh capital to strengthen its technology platform, enhance its AI-powered inventory intelligence, expand operational capabilities and grow its pharmacy network across new geographies.

Founded in 2024 by Aman Priyadarshi, Plazza is attempting to solve one of India’s biggest healthcare challenges, ensuring medicines prescribed by doctors are actually available when patients need them.

India’s pharmacy retail market, estimated to be worth more than $30 billion, is dominated by independent neighbourhood chemists that typically stock only around 5,000 medicines from a universe of more than 100,000 products. As a result, patients often have to visit multiple pharmacies to complete a prescription.

Plazza’s model combines neighbourhood pharmacies with AI-based inventory planning that predicts local demand and recommends which medicines each store should stock. The company said each outlet carries more than 40,000 stock keeping units (SKUs), the individual products tracked in inventory, enabling prescription fulfilment rates of more than 95% compared with the industry average of 50 to 60%. Medicines are claimed to be delivered within 15 to 30 minutes.

“Medicine availability shouldn’t depend on luck,” founder and chief executive officer Priyadarshi said. He added that patients should not have to visit multiple pharmacies or wait days because inventory is fragmented, and argued that pharmacy retail needs to be rebuilt around technology rather than shelves.

According to Priyadarshi, the new funding will strengthen the intelligence behind every Plazza store, expand into more neighbourhoods and create a pharmacy experience customers can consistently rely on.

The startup’s AI system continuously analyses prescribing patterns at the neighbourhood level, allowing every store to maintain a tailored inventory.

“What stood out to us about Plazza was not simply faster delivery but a fundamentally different operating model built around AI-driven inventory intelligence and neighbourhood-level demand,” said Chirag Chadha, Partner at Elevation Capital.

Since launch, the company claims to have grown its gross merchandise value (GMV), which measures the total value of transactions on a platform, nearly 27-fold between June 2025 and March 2026. Repeat customers now place orders with average basket sizes around 30% larger than first-time buyers, according to Plazaa.

Plazza’s latest round follows its $1.4 million seed funding announced in September 2025. More broadly, healthtech has remained one of the more resilient segments for venture funding in India despite a cautious investment climate, with investors continuing to back startups focused on improving healthcare access, operational efficiency and affordability.

Investors in the latest round believe Plazza’s competitive advantage lies in solving a structural problem rather than merely offering faster deliveries.

“Plazza is reversing this experience by combining deep pharmacy inventory, reliable local fulfilment, 24x7 access and a consumer-first technology layer,” noted Pratik Agarwal, Partner at Accel.